Method for producing beta-hydroxy-beta methylbutyric acid through double-enzyme co-expression
By optimizing the combination of RBS sequences in host cells to form a dual-enzyme co-expression system, the problem of enzyme expression imbalance in dual-enzyme cascade catalysis was solved, achieving efficient production of β-hydroxy-β-methylbutyric acid, which is suitable for the preparation of raw materials for pharmaceuticals, food additives and health products.
Patent Information
- Application Number
- CN202511972208.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-12-25
- Publication Date
- 2026-04-28
AI Technical Summary
In existing HMB biosynthesis technologies, the two-enzyme cascade catalysis suffers from enzyme expression imbalance leading to intermediate product accumulation, complex reaction steps, numerous side reactions, high costs, and difficulty in achieving efficient industrial production.
In host cells, L-amino acid deaminase and 4-hydroxyphenylpyruvate dioxygenase were expressed using the same promoter. By optimizing the ribosome binding site (RBS) sequence, the expression balance and efficient synergy of the two enzymes were achieved. A co-expression system was constructed, using the pET28a vector and the T7 promoter, and the RBS sequence combination was optimized to match the enzyme expression levels.
It improves the conversion efficiency from L-leucine to β-hydroxy-β-methylbutyric acid, achieving a yield of 14.12 mM and a molar conversion rate of 56.5%. It simplifies the operation process, reduces production costs, and is suitable for the preparation of raw materials for pharmaceuticals, food additives, and health products.
Smart Images

Figure CN121931189A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of enzyme engineering technology, and in particular to a method for producing β-hydroxy-β-methylbutyric acid by co-expression of two enzymes. Background Technology
[0002] β-Hydroxy-β-methylbutyric acid (HMB), a key metabolite of L-leucine in mammals, functions primarily by inhibiting protein breakdown through downregulation of proteasome activity, thereby effectively reducing muscle loss. Based on this unique bioactivity, HMB has been widely applied in multiple fields: as a feed additive in animal husbandry, as a human supplement in sports nutrition, and also extensively used in dietary food processing. Furthermore, it has shown significant application potential in the clinical treatment of muscular dystrophy syndromes caused by chronic diseases such as malignant tumors and acquired immunodeficiency syndromes, demonstrating broad commercial development prospects.
[0003] Currently, HMB synthesis technologies are mainly divided into two categories: chemical synthesis and biosynthesis. Industrial-scale production still primarily relies on chemical synthesis, which uses diacetone alcohol as the core substrate. However, this method poses significant environmental risks, such as the need for oxidants and the generation of toxic peroxidation byproducts, limiting its green application. Biosynthesis, with its advantages of high selectivity and mild reaction conditions, has become an ideal environmentally friendly alternative to chemical synthesis, and recent research has yielded several breakthroughs.
[0004] (1) Endogenous metabolic pathway conversion technology: In-Young Lee and JPN Rosazza (Archives of Microbiology, 1998) used the endogenous metabolic system of Galactomyces reessii to convert β-methylbutyric acid (MBA) into HMB using MBA as a substrate. After 136 hours of fermentation, a yield of 38 g / L was achieved, with a molar conversion rate of 50% and an average yield of 0.28 g / (L·h). However, this route has technical bottlenecks such as obvious substrate off-odor, complex operation process and fierce competition from metabolic bypass pathways.
[0005] (2) De novo synthesis: Sally J. Huang et al. (Metabolic Engineering, 2024) constructed a mevalonic acid pathway in Escherichia coli to achieve de novo synthesis of HMB using glucose as a carbon source. After 128 hours of reaction in a 1 L fermenter, the HMB yield was 17.7 g / L, the glucose conversion rate was 0.16 g / g, and the average yield was 0.14 g / (L·h). However, the substrate generalization of the decarboxylase led to the accumulation of byproducts, which significantly increased the difficulty and cost of downstream separation and purification.
[0006] (3) Dual-enzyme cascade catalysis technology: An enzyme cascade platform based on the synergistic catalysis of L-amino acid deaminase (L-AAD) and 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) has been developed. The reaction mechanism involves L-AAD first converting L-leucine into an imine intermediate, which spontaneously hydrolyzes to generate α-ketoisocaproic acid (α-KIC), which is then oxidatively decarboxylated by 4-HPPD to generate HMB. To improve catalytic efficiency, Ruichen Gao and Zhimin Li (Gao, R.; Li, ZJ Agric. Food Chem. 2021) mutated amino acid 341 of 4-HPPD (RnHPPD) from brown rat (Rattus norvegicus) to alanine, effectively reducing the steric hindrance of the substrate channel and increasing enzyme activity by 20% compared to the wild type. RnHPPD was co-cultured for expression. Q341A The HMB yield of *Escherichia coli* Rosetta (DE3) strain derived from *Proteus vulgaris* L-AAD (PvLAAD) reached 1.4 g / L after 10 hours, with an average yield of 0.14 g / (L·h). This technology has significant advantages such as simple reaction steps, few side reactions, and low substrate cost. However, it still faces the key problem of the imbalance between the expression levels of the two enzymes, leading to the large accumulation of the intermediate product α-KIC, which urgently needs further optimization. Summary of the Invention
[0007] To address the aforementioned technical problems, this invention uses the same promoter in host cells to express L-amino acid deaminase and 4-hydroxyphenylpyruvate dioxygenase. By optimizing and screening the ribosome binding site (RBS) sequence, the key RBS combination was determined, achieving balanced expression and efficient synergy of the two enzymes.
[0008] The first objective of this invention is to provide a method for producing β-hydroxy-β-methylbutyric acid by co-expressing L-amino acid deaminase and 4-hydroxyphenylpyruvate dioxygenase in host cells, using L-leucine as a substrate.
[0009] The L-amino acid deaminase encoding gene and the 4-hydroxyphenylpyruvate dioxygenase encoding gene are expressed by the same promoter in the same expression vector, and the L-amino acid deaminase encoding gene is located upstream of the 4-hydroxyphenylpyruvate dioxygenase encoding gene.
[0010] Furthermore, the expression vector uses pET28a as its backbone.
[0011] Furthermore, the expression vector uses the T7 promoter.
[0012] Furthermore, the expression vector uses the T7 terminator.
[0013] Furthermore, the host cell is Escherichia coli BL21(DE3).
[0014] Furthermore, the upstream of the L-amino acid deaminase encoding gene also includes a first RBS sequence, as shown in SEQ ID NO.3 or SEQ ID NO.6.
[0015] Furthermore, the first RBS sequence is shown in SEQ ID NO.3.
[0016] Furthermore, the upstream of the 4-hydroxyphenylpyruvate dioxygenase encoding gene also includes a second RBS sequence, the second RBS sequence being any one of SEQ ID NO.3, SEQ ID NO.18, SEQ ID NO.19 and SEQ ID NO.21.
[0017] Furthermore, the second RBS sequence is shown in SEQ ID NO.21.
[0018] The second objective of this invention is to provide an expression vector for co-expressing L-amino acid deaminase and 4-hydroxyphenylpyruvate dioxygenase, wherein the L-amino acid deaminase encoding gene and the 4-hydroxyphenylpyruvate dioxygenase encoding gene are expressed by the same promoter, and the L-amino acid deaminase encoding gene is located upstream of the 4-hydroxyphenylpyruvate dioxygenase encoding gene.
[0019] The L-amino acid deaminase encoding gene also includes a first RBS sequence upstream, as shown in SEQ ID NO.3 or SEQ ID NO.6;
[0020] The 4-hydroxyphenylpyruvate dioxygenase encoding gene also includes a second RBS sequence upstream, as shown in any one of SEQ ID NO.3, SEQ ID NO.18, SEQ ID NO.19 and SEQ ID NO.21.
[0021] Further, the first RBS sequence is as shown in SEQ ID NO.3, and the second RBS sequence is as shown in SEQ ID NO.21.
[0022] A third objective of this invention is to provide an Escherichia coli that contains the above-described expression vector.
[0023] Furthermore, the Escherichia coli is Escherichia coli BL21(DE3).
[0024] A fourth objective of this invention is to provide a microbial agent containing the aforementioned Escherichia coli.
[0025] A fifth objective of this invention is to provide the use of the above-described expression vector, the above-described Escherichia coli, or the above-described microbial agent in the production of β-hydroxy-β-methylbutyric acid.
[0026] The beneficial effects of this invention are:
[0027] This invention creatively constructs a co-expression system by placing L-amino acid deaminase and 4-hydroxyphenylpyruvate dioxygenase downstream of the same promoter and in a specific order. By carefully screening and combining different RBS sequences, the expression levels and activities of the two enzymes are optimally matched, significantly improving the conversion efficiency and final yield from L-leucine to β-hydroxy-β-methylbutyric acid. The highest yield reaches 14.12 mM, with a molar conversion rate of 56.5%. This effectively guides metabolic flux, reduces the accumulation of intermediate products, and makes the entire two-step enzymatic reaction process smoother and more efficient. This invention achieves highly efficient co-expression of the two enzymes using a single vector and a single induction condition, simplifying genetic manipulation and fermentation processes, improving the stability and reproducibility of the production system, and contributing to reduced industrial production costs. It is applicable to the preparation of raw materials in multiple fields such as pharmaceuticals, food additives, and health products, possessing significant economic and social value. Attached Figure Description
[0028] To make the content of this invention easier to understand, the invention will be further described in detail below with reference to specific embodiments and accompanying drawings, wherein:
[0029] Figure 1 This is a schematic diagram of the process for producing β-hydroxy-β-methylbutyric acid by co-expression of two enzymes as described in this invention;
[0030] Figure 2 The pHL and pLH recombinant plasmid structures obtained in Example 1 of this invention;
[0031] Figure 3 In Example 1 of this invention, recombinant plasmids pHL and pLH were transformed into expression host *Escherichia coli* BL21(DE3) for whole-cell transformation, and the product concentration was measured after 10 h of reaction.
[0032] Figure 4 In Example 2 of this invention, 14 recombinant plasmids pHL1-14 were transformed into expression host Escherichia coli BL21(DE3) for whole-cell transformation. Detailed Implementation
[0033] The present invention will be further described below with reference to the accompanying drawings and specific embodiments, so that those skilled in the art can better understand and implement the present invention. However, the embodiments described are not intended to limit the present invention.
[0034] The materials and methods involved in the following embodiments are as follows:
[0035] Recombinant Escherichia coli seed culture and fermentation:
[0036] LB medium: 10 g / L tryptone, 10 g / L sodium chloride, 5 g / L yeast extract.
[0037] TB medium: 12 g / L tryptone, 24 g / L yeast extract, 16.43 g / L dipotassium hydrogen phosphate trihydrate, 2.31 g / L potassium dihydrogen phosphate, 4 mL / L glycerol.
[0038] Whole-cell transformation process: First, a single colony was picked and transferred to 1 mL of LB medium and cultured at 37°C and 220 rpm for 12 hours. Then, 0.25 mL of the seed culture was transferred to 25 mL of TB medium, and kanamycin was added. The culture was then incubated at 37°C and 220 rpm until OD reached [value missing]. 600 =0.6-0.8, add IPTG inducer to a final concentration of 0.5 mM, and induce culture at 30℃ and 220 rpm for 12 h. Collect bacterial cells by centrifugation at 5000 rpm for 10 min and wash twice with 20 mM Tris-maleic acid buffer (pH=5.5). For whole-cell catalysis, resuspend the bacterial cells in a 10 mL reaction system containing 25 mM L-leucine, 1 mM FeSO4·7H2O (containing 1 mM dithiothreitol), and 60 mM Tris-maleic acid buffer (pH 5.5), ultimately preparing OD. 600 =45 bacterial suspension.
[0039] Sample detection method: HMB and the intermediate α-KIC were detected using an Agilent high-performance liquid chromatography (HPLC) system equipped with a 210 nm UV absorber and an Aminex HPX-87H column (300 × 7.8 mm, Bio-Rad). The fermentation broth was collected and centrifuged at 12,500 rpm for 3 minutes. The supernatant was mixed with 35 mM sulfuric acid solution at a 1:2 ratio to remove soluble proteins, and then centrifuged again at 14,000 rpm for 10 minutes. The sample was filtered through a 0.22 μm filter before detection. Chromatographic conditions were: mobile phase 10 mM sulfuric acid solution, flow rate 0.5 mL / min, column temperature 40 ℃, and injection volume 10 μL.
[0040] Example 1: Co-expression of two enzymes at different gene positions
[0041] Based on the imbalance in dual-enzyme co-expression, two recombinant plasmids were constructed by comparing the positions of the two enzymes before and after the promoter to achieve single-promoter single-plasmid co-expression of AaHPPD and PvLAAD. AaHPPD (amino acid sequence shown in SEQ ID NO.1) from *Allokutzneria albata* and PvLAAD (amino acid sequence shown in SEQ ID NO.2) from *Proteus vulgaris* were selected to construct dual-enzyme co-expression plasmids. Primers were designed to obtain recombinant fragments, which were then ligated to the pET28a plasmid via Gibson assembly to construct two recombinant plasmids: pHL(P... T7 -RBS0-AaHPPD-RBS0-PvLAAD-T) and pLH (P T7 -RBS0-PvLAAD-RBS0-AaHPPD-T), the nucleotide sequence of RBS0 is shown in SEQ ID NO.3, and the plasmid structure is as follows. Figure 1 As shown.
[0042] Recombinant plasmids pHL and pLH were transformed into expression host *E. coli* BL21(DE3) for whole-cell transformation. Product concentration was measured after 10 hours of reaction. Results are as follows: Figure 2 As shown, under the same conditions, the host bacteria transformed with the pHL recombinant plasmid had the highest HMB yield in the final reaction solution, approximately 8.38 mM, with a molar conversion rate of 33.5%.
[0043] Example 2: Co-expression of two enzymes with RBS sequences of different combined strengths
[0044] After transcription initiation, the ribosome binding site (RBS) binds to the ribosome to initiate the translation process. Modifying the RBS sequence adjusts the initiation translation intensity, coordinating the expression intensity of the two enzymes, and further alleviating the problem of intermediate product accumulation. As shown in Table 1, based on the translation initiation rate (from high to low), 10 RBS sequences of different intensities from the RBS prediction library were selected for each of the two genes to replace the original RBS, as shown in SEQ ID NO. 4-24. These RBS sequences were then combined in pairs to express the entire expression cassette (P... T7 -RBSx-AaHPPD-RBSy-PvLAAD-T, where RBSx is used to express AaHPPD and RBSy is used to express PvLAAD) were input into the RBS calculator website to evaluate the initial translation rate of each gene, and different RBS combinations were selected to construct 14 co-expression plasmids pHL1-14 (as shown in Table 2).
[0045] Table 1 RBS sequences and predicted intensities
[0046]
[0047] Table 2. Combinations of RBS sequences with different intensities
[0048]
[0049] Fourteen recombinant plasmids, pHL1-14, were transformed into the expression host *E. coli* BL21(DE3) for whole-cell transformation. Product concentrations were measured after 10 h of reaction. Results are as follows: Figure 3 As shown, under the same conditions, the host bacteria containing the pHL1 recombinant plasmid had the highest HMB yield in the final reaction solution, approximately 14.12 mM, with a molar conversion rate of 56.5%. The HMB yields of pHL2, pHL3, and pHL6 were also significantly higher than those of pHL.
[0050] Obviously, the above embodiments are merely illustrative examples for clear explanation and are not intended to limit the implementation. Those skilled in the art will recognize that other variations or modifications can be made based on the above description. It is neither necessary nor possible to exhaustively list all possible implementations here. However, obvious variations or modifications derived therefrom are still within the scope of protection of this invention.
Claims
1. A method for producing β-hydroxy-β-methylbutyric acid, characterized in that: L-amino acid deaminase and 4-hydroxyphenylpyruvate dioxygenase are co-expressed in the host cell and produced using L-leucine as a substrate. The L-amino acid deaminase encoding gene and the 4-hydroxyphenylpyruvate dioxygenase encoding gene are expressed by the same promoter in the same expression vector, and the L-amino acid deaminase encoding gene is located upstream of the 4-hydroxyphenylpyruvate dioxygenase encoding gene.
2. The method according to claim 1, characterized in that: The expression vector uses pET28a as its backbone.
3. The method according to claim 1, characterized in that: The host cell was Escherichia coli BL21(DE3).
4. The method according to claim 1, characterized in that: The upstream of the L-amino acid deaminase encoding gene also includes a first RBS sequence, as shown in SEQ ID NO.3 or SEQ ID NO.
6.
5. The method according to claim 1, characterized in that: The 4-hydroxyphenylpyruvate dioxygenase encoding gene also includes a second RBS sequence upstream, as shown in any one of SEQ ID NO.3, SEQ ID NO.18, SEQ ID NO.19 and SEQ ID NO.
21.
6. An expression vector for co-expressing L-amino acid deaminase and 4-hydroxyphenylpyruvate dioxygenase, characterized in that: The L-amino acid deaminase encoding gene and the 4-hydroxyphenylpyruvate dioxygenase encoding gene are expressed by the same promoter, and the L-amino acid deaminase encoding gene is located upstream of the 4-hydroxyphenylpyruvate dioxygenase encoding gene; The L-amino acid deaminase encoding gene also includes a first RBS sequence upstream, as shown in SEQ ID NO.3 or SEQ ID NO.6; The 4-hydroxyphenylpyruvate dioxygenase encoding gene also includes a second RBS sequence upstream, as shown in any one of SEQ ID NO.3, SEQ ID NO.18, SEQ ID NO.19 and SEQ ID NO.
21.
7. The expression vector according to claim 6, characterized in that: The first RBS sequence is shown in SEQ ID NO.3, and the second RBS sequence is shown in SEQ ID NO.
21.
8. An Escherichia coli, characterized in that: The *Escherichia coli* comprises the expression vector of claim 6 or 7.
9. A microbial agent containing the Escherichia coli of claim 8.
10. The use of the expression vector of claim 6 or 7, the Escherichia coli of claim 8, or the microbial agent of claim 9 in the production of β-hydroxy-β-methylbutyric acid.
